Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

Indonesia’s Randy Bintang shot an impressive five-under 65 to surge to the top of the leaderboard after round one of the Asia ...

Researchers from the University of Alabama at Birmingham have identified a promising new combination therapy for metastatic ...

Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...

Receptors such as EGFR, HER2, MET and ALK interface with common downstream signaling pathways and 'addiction switching' can occur, either by the inhibition of one receptor triggering a switch to ...

The FDA on Thursday approved xanomeline and trospium chloride (Cobenfy) for schizophrenia in adults, the first new class of ...

Munich, Germany, October 1, 2024 – (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the ...

These findings expose a broad gap in screening for chronic kidney disease that is especially concerning now that there are ...

Researchers mapped the biological influences on 4,775 plasma proteins, revealing the interplay of modifiable and ...

The new SCLC-type tumors are resistant to anti-EGFR therapy because their growth is fueled by a new cancer driver, high levels of Myc protein. To unravel the interplay of these cancer pathways, the ...

Researchers hope DeepGEM can expedite targeted treatment for lung cancer patients who can't access standard genomic testing.

The number of new drugs approved each year increased steadily in the first few years of the analysis period, and more than 40 ...